| Zhang, Yan |
NCT04790305: Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer |
|
|
| Recruiting | 4 | 1072 | RoW | Huaier Granule, Z20000109（NMPA Approval Number） | Fudan University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology | Carcinoma Breast, Triple-negative Breast Cancer, Invasive Ductal Carcinoma, Breast | 12/27 | 07/28 | | |
ETER701, NCT04234607: A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer |
|
|
| Not yet recruiting | 3 | 738 | RoW | TQB2450, Anlotinib, Etoposide, Carboplatin, TQB2450（blank）, Anlotinib（blank) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Extensive Small Cell Lung Cancer | 12/22 | 12/22 | | |
| Active, not recruiting | 3 | 453 | Europe, US, RoW | MRTX849, adagrasib, KRAZATI, Docetaxel, Taxotere | Mirati Therapeutics Inc., Mirati Therapeutics, Inc. | Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer | 12/23 | 12/24 | | |
|
NCT05181137 / 2021-001940-86: A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 3 | 368 | Europe, US, RoW | SHR0302, Placebo | Reistone Biopharma Company Limited, Reistone Biopharma Company Limited | Ulcerative Colitis | 10/24 | 03/25 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
LEAD, NCT05092412: Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC |
|
|
| Active, not recruiting | 2 | 30 | RoW | Low-dose radiotherapy, Durvalumab, Etoposide, and cisplatin/carboplatin | You Lu, AstraZeneca | Lung Cancer, Extensive-stage Small-cell Lung Cancer, Durvalumab | 02/23 | 06/25 | | |
NCT06632262: A Phase 2 Clinical Study of ABSK061 and ABSK043 |
|
|
| Not yet recruiting | 2 | 202 | RoW | ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX | Abbisko Therapeutics Co, Ltd | HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors | 11/29 | 06/30 | | |
FOCUS-C, NCT05334277: Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA |
|
|
| Recruiting | 2 | 280 | RoW | Furmonertinib, AST2818, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab | Sun Yat-sen University, Allist Pharmaceuticals, Inc., GeneCast Biotechnology Co., Ltd. | Non-small Cell Lung Cancer | 02/25 | 02/28 | | |
NCT05867771: A Study of PM1022 in Patients With Advanced Tumors |
|
|
| Recruiting | 1/2 | 200 | RoW | PM1022 | Biotheus Inc. | Advanced Tumors | 04/24 | 04/25 | | |
NCT05416775: Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 168 | RoW | SHR-8068；Adebrelimab, SHR-8068；adebrelimab and platinum-based chemotherapy, Adebrelimab；platinum-based chemotherapy | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Non-small Cell Lung Cancer | 06/26 | 06/26 | | |
NCT05245916: IBI397 or Combination Therapies in Patients With Advanced Malignancies |
|
|
| Withdrawn | 1a/1b | 30 | RoW | IBI397, IBI397+Sintilimab, IBI397+Rituximab | Innovent Biologics (Suzhou) Co. Ltd. | Advanced Malignancies | 08/23 | 08/23 | | |
NCT04487093: Clinical Study of Neoantigen Vaccine Combined With Targeted Drugs in the Treatment of Non-small Cell Lung Cancer |
|
|
| Recruiting | 1 | 20 | RoW | neoantigen vaccine + EGFR-TKI, neoantigen vaccine + anti-angioge | First Hospital of Shijiazhuang City, Tianjin Hengjia Biotechnology Development co., LTD | Non Small Cell Lung Cancer | 05/22 | 12/22 | | |
| Recruiting | 1 | 132 | Japan, RoW | SHR-A2009 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Solid Tumors | 12/23 | 12/24 | | |
NCT05508334: A Study to Assess the Safety and Tolerability of RC88 for Patients with Advanced Solid Tumours |
|
|
| Active, not recruiting | 1 | 81 | RoW | RC88, The injectable RC88 | RemeGen Co., Ltd. | Advanced Solid Tumours | 06/25 | 12/25 | | |
| Recruiting | 1 | 156 | US, RoW | CS5001 | CStone Pharmaceuticals | Advanced Solid Tumor, Advanced Lymphoma | 03/25 | 06/25 | | |
|
NCT06384352: A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 155 | Canada, US, RoW | YL211 | MediLink Therapeutics (Suzhou) Co., Ltd., Hoffmann-La Roche | Advanced Solid Tumors | 04/27 | 04/29 | | |
UltraFuture I, NCT05498740: Post-marketing Study in Femoral Popliteal Artery of Drug Coated Balloon Used for Treatment of Lower Limb Ischemia |
|
|
| Recruiting | N/A | 200 | RoW | Drug eluting Balloon | Zhejiang Zylox Medical Device Co., Ltd. | Peripheral Arterial Disease (PAD) | 12/22 | 12/24 | | |
DELTA, NCT05608655: DKutting Balloon Versus Chocolate Balloon to Treat Femoral and Popliteal Artery Stenosis |
|
|
| Completed | N/A | 188 | RoW | DKutting LL balloon, Chocolate balloon | DK Medical Technology (Suzhou) Co., Ltd. | Femoral Artery Stenosis, Popliteal Artery Stenosis | 01/24 | 02/24 | | |
| Not yet recruiting | N/A | 768 | RoW | early pancreatic stent placement (EPSP), late pancreatic stent placement (EPSP) | The First Affiliated Hospital of Anhui Medical University, First Affiliated Hospital Bengbu Medical College, Anqing Municipal Hospital, First Affiliated Hospital of Wannan Medical College, Tongcheng People's Hospital of Anhui province, Fuyang people's hospital | Cholangiopancreatography, Endoscopic Rretrograde, Post-ERCP Pancreatitis | 03/26 | 03/26 | | |
| Ding, Changhai |
GNC-035-103, NCT05160545: A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer |
|
|
| Recruiting | 1 | 29 | RoW | GNC-035 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Breast Cancer | 06/25 | 12/25 | | |
NCT05339685: A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors |
|
|
| Recruiting | 1 | 26 | RoW | BL-M02D1 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Breast Cancer | 12/24 | 12/24 | | |
| Liu, Jun |
NCT05908695: An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease |
|
|
| Recruiting | 4 | 1312 | RoW | GV-971, Placebo | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Alzheimer's Disease | 06/29 | 12/29 | | |
NCT05092841: A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A |
|
|
| Completed | 3 | 176 | RoW | PXT3003, (RS)-baclofen, naltrexone hydrochloride and D-sorbitol oral fixed dose combination, PXT3003 placebo, liquid oral solution | Tasly GeneNet Pharmaceuticals Co., Ltd | Charcot-Marie-Tooth Type 1A | 03/24 | 03/24 | | |
NCT05862337: Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence. |
|
|
| Recruiting | 3 | 480 | RoW | Anlotinib hydrochloride capsules, Penpulimab injection, Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hepatocellular Carcinoma | 08/24 | 12/26 | | |
| Recruiting | 3 | 1200 | Europe, Canada, Japan, US, RoW | Remternetug, LY3372993, Placebo | Eli Lilly and Company | Alzheimer's Disease | 04/29 | 10/30 | | |
NCT05811442: Study of 50561 in Patients With Mild or Moderate Alzheimer's Disease |
|
|
| Recruiting | 2a | 60 | RoW | 50561 high dose, 50561 low dose, Placebo | Beijing Joekai Biotechnology LLC | Alzheimer's Disease | 05/24 | 06/24 | | |
NCT05336539: A Community Population Screening Cohort Study Based on Polygene Methylation Detection for Colorectal Cancer in Yangzhou |
|
|
| Recruiting | N/A | 80000 | RoW | | Singlera Genomics Inc., Northern Jiangsu Province People's Hospital | Colorectal Cancer | 04/27 | 04/27 | | |
| Chen, Xin |
TQB2450-III-09, NCT04964479: A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC) |
|
|
| Recruiting | 3 | 375 | RoW | TQB2450 injection, Anlotinib Hydrochloride Capsules, Pembrolizumab injection, Placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 12/22 | 03/23 | | |
NCT05003245: Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD |
|
|
| Recruiting | 3 | 388 | RoW | HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis | Shanghai Henlius Biotech | Age Related Macular Degeneration | 08/23 | 03/24 | | |
NCT06301854: Long-term Safety of TPN171H Tablet in Erectile Dysfunction. |
|
|
| Recruiting | 3 | 472 | RoW | TPN171H, Simmerafil | Vigonvita Life Sciences | Erectile Dysfunction | 04/25 | 04/25 | | |
NCT04937387: Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma |
|
|
| Completed | 3 | 359 | RoW | FF/VI, FF/UMEC/VI, ELLIPTA | GlaxoSmithKline | Asthma | 08/24 | 08/24 | | |
| Recruiting | 1/2 | 60 | RoW | PM8002, nab-paclitaxel | Biotheus Inc. | TNBC | 10/26 | 10/26 | | |
NCT05001412: Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC |
|
|
| Recruiting | 1 | 36 | RoW | Camrelizumab; apatinib; carboplatin; etoposide | Zhou Chengzhi, Jiangsu Hengrui Pharmaceutical Co., Ltd. | Extensive Stage Small Cell Lung Cancer | 01/23 | 01/24 | | |
| Recruiting | N/A | 1017 | US, RoW | Infuse™ Bone Graft (Infuse™), Intervertebral body fusion device and Medtronic posterior Fixation Systems | Medtronic Spinal and Biologics | Degenerative Disease of the Lumbosacral Spine | 04/26 | 04/28 | | |
| Active, not recruiting | N/A | 255 | RoW | EDWARDS INSPIRIS RESILIA Aortic Valve | Edwards Lifesciences, Edwards (Shanghai) Lifesciences Medical Supplies Co., Ltd., Rundo International Pharmaceutical Research & Development Co.,Ltd., Fuwai Hospital, CAMS & PUMC | Aortic Valve Replacement | 12/28 | 12/29 | | |
| Weng, Xisheng |
MARS-17, NCT05838742: A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adults With Knee Osteoarthritis (OA) Pain |
|
|
| Active, not recruiting | 2 | 314 | Europe, Canada, Japan, US, RoW | GSK3858279, Placebo | GlaxoSmithKline | Pain, Osteoarthritis, Knee | 08/24 | 12/24 | | |
| Li, Qi |
| Active, not recruiting | 4 | 1127 | RoW | Yangzheng Compound Mixture, Z10970042（NMPA Approval Number）, Conventional Treatment | ShuGuang Hospital, LinkDoc Technology (Beijing) Co. Ltd., Shaanxi Buchang Pharmaceutical Co., Ltd | Carcinoma, Sleep Disorder | 09/23 | 06/24 | | |
SELECT-2, NCT04401059: Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study |
|
|
| Recruiting | 4 | 744 | RoW | Elemene plus first or third generation EGFR-TKIs, H10960114, H20010338, First or third generation EGFR-TKIs, Gefitinib(Iressa,YiRuiKe), Erlotinib(Tarceva), Icotinib(Kaimeina), Osimertinib(Tagrisso), Almonertinib, Furmonertinib, etc. | Tian Xie, LinkDoc Technology (Beijing) Co. Ltd. | Carcinoma, Non-Small-Cell Lung Cancer, Adenocarcinoma | 09/25 | 03/26 | | |
NCT04385550: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 3 | 528 | RoW | Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma | 10/23 | 12/23 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
NCT04412564: A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor |
|
|
| Recruiting | 2 | 200 | RoW | TQ-B3101 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Malignant Tumor | 03/21 | 09/21 | | |
| Recruiting | 2 | 69 | RoW | Regorafenib Pill&Camrelizumab | Nanfang Hospital of Southern Medical University, Jiangsu HengRui Medicine Co., Ltd. | Hepatocellular Carcinoma | 01/22 | 01/22 | | |
SPH5030-201, NCT06434597: A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients. |
|
|
| Recruiting | 2 | 60 | RoW | SPH5030 | Shanghai Pharmaceuticals Holding Co., Ltd | Biliary Tract or Colorectal Cancer With Her2-positive/Mutated | 12/26 | 12/26 | | |
NCT06212076: Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients |
|
|
| Not yet recruiting | 1/2 | 60 | RoW | IPG1094 | Nanjing Immunophage Biotech Co., Ltd | Solid Tumor | 07/24 | 08/24 | | |
| Recruiting | 1/2 | 103 | RoW | TQB2102 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Biliary Tract Cancer | 05/25 | 12/25 | | |
NCT04606472: A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 159 | RoW | SI-B003 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc. | Solid Tumor | 06/25 | 06/25 | | |
| Recruiting | 1 | 12 | RoW | SN301A, Fludarabine, Cyclophosphamide | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Celest Therapeutics Co. Ltd, Senti Biosciences | Hepatocellular Carcinoma (HCC) | 10/26 | 10/27 | | |
| Recruiting | 1 | 48 | RoW | SM3321 | Beijing StarMab Biomed Technology Ltd | Locally Advanced or Metastatic Solid Tumors | 08/25 | 10/25 | | |
SELECT-1, NCT04397432: Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Retrospective Study |
|
|
| Active, not recruiting | N/A | 878 | RoW | | Tian Xie, LinkDoc Technology (Beijing) Co. Ltd. | Carcinoma, Non-Small-Cell Lung | 04/23 | 03/26 | | |
| yang, li |
NCT05463965: A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines |
|
|
| Completed | 3 | 605 | RoW | QM1114-DP, OnabotulinumtoxinA, Placebo | Galderma R&D | Moderate to Severe Glabellar Lines | 01/23 | 06/23 | | |
NCT06775860: ICP-332 in Subjects with Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 552 | RoW | ICP-332 Tablets, ICP-332 Placebo Tablets | Beijing InnoCare Pharma Tech Co., Ltd. | Atopic Dermatitis | 11/26 | 12/26 | | |
METIS, NCT02831959: Pivotal, Open-label, Randomized Study of Radiosurgery with or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC). |
|
|
| Completed | 3 | 298 | Europe, Canada, US, RoW | NovoTTF-200M device, Best Standard of Care | NovoCure GmbH | Brain Metastases from Non-small Cell Lung Cancer (NSCLC) | 11/24 | 11/24 | | |
| Active, not recruiting | 2/3 | 350 | Europe, Japan, US, RoW | Abemaciclib, LY2835219, Abiraterone Acetate, Prednisone, Placebo | Eli Lilly and Company | Prostate Cancer | 01/24 | 06/26 | | |
NCT06413654: A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) |
|
|
| Recruiting | 2/3 | 132 | RoW | B001, Placebo | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Neuromyelitis Optica Spectrum Disorders | 10/27 | 02/29 | | |
NCT04492293: An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer |
|
|
| Recruiting | 2 | 115 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Bladder Urothelial Cancer | 12/24 | 06/25 | | |
NCT06123858: Non-alcoholic Steatohepatitis Registry Platform Study |
|
|
| Recruiting | N/A | 2500 | RoW | | AstraZeneca | NASH With Fibrosis | 12/26 | 12/26 | | |
| Wang, Qian |
NCT05024214: Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors |
|
|
| Recruiting | 1/2 | 170 | RoW | Lenvatinib + Envafolimab, Sunitinib | 3D Medicines (Sichuan) Co., Ltd. | Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma | 12/24 | 12/24 | | |
NCT04448379: Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1 | 48 | RoW | JMT101, Afatinib or Osimertinib | Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 12/21 | 06/22 | | |
| Duan, Chuanzhi |
EMPOWER, NCT04289480: Safety and Effectiveness of ENTERPRISE 2 Device in the Endovascular Treatment of Intracranial Aneurysms |
|
|
| Active, not recruiting | N/A | 164 | RoW | ENTERPRISE 2 device | Medos International SARL, Johnson & Johnson Medical (Shanghai) Ltd. | Intracranial Aneurysm | 04/22 | 01/27 | | |
NCT05058482: Non-adhesive Liquid Embolic System in the Embolization of Cerebral Arteriovenous Malformations |
|
|
| Recruiting | N/A | 116 | RoW | embolism | Suzhou Hengruihongyuan Medical Technology Co. LTD | Intracranial Arteriovenous Malformations | 10/23 | 10/24 | | |
NCT05898893: PARAT PLUS (The Tubridge Plus For The Treatment Of Wide-Necked Intracranial Aneurysms) |
|
|
| Recruiting | N/A | 99 | RoW | Microport NeuroTech Tubridge Plus flow-diverter Stent | MicroPort NeuroTech Co., Ltd. | Intracranial Aneurysm | 03/24 | 12/24 | | |
NCT06479343: Efficacy and Safety of the Liquid Embolic System (Tonbridge) for Endovascular Treatment of Cerebrovascular Malformations |
|
|
| Recruiting | N/A | 170 | RoW | Liquid Embolic System (Tonbridge), Onyx Liquid Embolic System (Medtronic) | Zhuhai Tonbridge Medical Tech. Co., Ltd. | Intracranial Arteriovenous Malformations | 10/25 | 10/26 | | |
NCT05755516: Efficacy and Safety of the Self-expanding Intracranial Stent (Tonbridge) for Endovascular Treatment of Intracranial Aneurysms |
|
|
| Active, not recruiting | N/A | 204 | RoW | Self-expanding Intracranial Stent (Tonbridge), LVIS and LVIS Jr. (MicroVention) | Zhuhai Tonbridge Medical Tech. Co., Ltd. | Intracranial Aneurysm | 10/24 | 04/25 | | |
| Zhang, Tangde |
NCT05470413: Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata |
|
|
| Active, not recruiting | 3 | 330 | RoW | SHR0302, Placebo | Reistone Biopharma Company Limited | Alopecia Areata | 10/23 | 02/24 | | |
| Wu, Wen |
NCT06552429: Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET |
|
|
| Recruiting | 2 | 27 | RoW | Peginterferon α-2b injection | Xiamen Amoytop Biotech Co., Ltd. | Essential Thrombocythemia | 09/25 | 09/27 | | |
NCT06122831: A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF) |
|
|
| Recruiting | 1/2 | 92 | RoW | TQ05105 Tablets, TQB3617 Capsules | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Myelofibrosis | 12/26 | 04/27 | | |
NCT05409482: A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 300 | RoW | | Meng Chao Hepatobiliary Hospital of Fujian Medical University, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Hepatocellular Carcinoma | 03/26 | 03/26 | | |
| Lei, Guanghua |
NCT05752461: SHR-2004 for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty |
|
|
| Recruiting | 2 | 316 | RoW | SHR-2004 injection, Enoxaparin sodium injection | Beijing Suncadia Pharmaceuticals Co., Ltd | Prevention of Venous Thromboembolism After Knee Arthroplasty | 06/24 | 09/24 | | |
| Zhao, Liang |
NCT03789760: The Clinical Trial of Chinese Herbal Medicine (SaiLuoTong) Capsule |
|
|
| Completed | 3 | 493 | RoW | SaiLuoTong capsule, The effects of SaiLuoTong capsule on VaD, placebo | Shineway Pharmaceutical Co.,Ltd | Vascular Dementia | 03/24 | 05/24 | | |
| Tian, Jing |
NCT05688696: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus |
|
|
| Recruiting | 2 | 186 | RoW | Orelabrutinib (Low Dose), Orelabrutinib (High Dose), Orelabrutinib Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Systemic Lupus Erythematosus, SLE | 08/25 | 05/26 | | |
NCT06010901: A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer. |
|
|
| Recruiting | 1 | 75 | RoW | TQB2618 injection, Penpulimab injection, Anlotinib hydrochloride capsules | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Colorectal Cancer | 03/25 | 07/25 | | |
| Liu, Chunxiao |
NCT05024214: Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors |
|
|
| Recruiting | 1/2 | 170 | RoW | Lenvatinib + Envafolimab, Sunitinib | 3D Medicines (Sichuan) Co., Ltd. | Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma | 12/24 | 12/24 | | |
| Jeudy, Wilner E |
NCT05171673: Study of PK and Safety of the LicartTM Topical System in Pediatric and Adult Participants with Minor Soft Tissue Injury |
|
|
| Completed | 3 | 151 | US | Licart™ (diclofenac epolamine) topical system, diclofenac epolamine | IBSA Institut Biochimique SA | Soft Tissue Injuries | 06/24 | 07/24 | | |
| Recruiting | 3 | 1200 | Europe, Canada, Japan, US, RoW | Remternetug, LY3372993, Placebo | Eli Lilly and Company | Alzheimer's Disease | 04/29 | 10/30 | | |
TRIUMPH-5, NCT06662383: A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity |
|
|
| Recruiting | 3 | 800 | Europe, US, RoW | Retatrutide, LY3437943, Tirzepatide, LY3298176 | Eli Lilly and Company | Obesity | 04/27 | 04/27 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) |
|
|
| Active, not recruiting | 3 | 2196 | Japan, US | Donanemab, LY3002813, Placebo | Eli Lilly and Company | Alzheimer Disease | 11/27 | 11/27 | | |
| Guo, Hongbo |
| Recruiting | 3 | 1200 | Europe, Canada, Japan, US, RoW | Remternetug, LY3372993, Placebo | Eli Lilly and Company | Alzheimer's Disease | 04/29 | 10/30 | | |
NCT04794972: A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 147 | RoW | GNC-039 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc. | Recurrent Glioma, Solid Tumor | 06/25 | 06/25 | | |
| Recruiting | N/A | 358 | RoW | early detection test | Zhujiang Hospital, Guangzhou Burning Rock Dx Co., Ltd. | Intracranial Tumors | 12/23 | 06/24 | | |
| Ning, Zeng |
| No trials found |
